Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1973 1
1975 1
1977 2
1978 1
1979 1
1980 2
1981 6
1982 4
1983 2
1984 3
1985 2
1986 3
1987 2
1988 8
1989 5
1990 10
1991 9
1992 11
1993 22
1994 29
1995 38
1996 27
1997 48
1998 38
1999 56
2000 86
2001 91
2002 116
2003 138
2004 180
2005 211
2006 230
2007 262
2008 336
2009 405
2010 505
2011 613
2012 693
2013 732
2014 758
2015 848
2016 789
2017 847
2018 918
2019 922
2020 999
2021 1021
2022 699
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

11,335 results
Results by year
Filters applied: . Clear all
Page 1
Inhibition of nonalcoholic fatty liver disease in mice by selective inhibition of mTORC1.
Gosis BS, Wada S, Thorsheim C, Li K, Jung S, Rhoades JH, Yang Y, Brandimarto J, Li L, Uehara K, Jang C, Lanza M, Sanford NB, Bornstein MR, Jeong S, Titchenell PM, Biddinger SB, Arany Z. Gosis BS, et al. Among authors: jung s. Science. 2022 Apr 15;376(6590):eabf8271. doi: 10.1126/science.abf8271. Epub 2022 Apr 15. Science. 2022. PMID: 35420934
Edoxaban Versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism After TAVR: The ADAPT-TAVR Randomized Clinical Trial.
Park DW, Ahn JM, Kang DY, Kim KW, Koo HJ, Yang DH, Jung SC, Kim B, Wong YTA, Lam CCS, Yin WH, Wei J, Lee YT, Kao HL, Lin MS, Ko TY, Kim WJ, Kang SH, Yun SC, Lee SA, Ko E, Park H, Kim DH, Kang JW, Lee JH, Park SJ; ADAPT-TAVR Investigators. Park DW, et al. Among authors: jung sc. Circulation. 2022 Aug 9;146(6):466-479. doi: 10.1161/CIRCULATIONAHA.122.059512. Epub 2022 Apr 4. Circulation. 2022. PMID: 35373583 Clinical Trial.
Targeted Immunotherapy for Autoimmune Disease.
Jung SM, Kim WU. Jung SM, et al. Immune Netw. 2022 Feb 17;22(1):e9. doi: 10.4110/in.2022.22.e9. eCollection 2022 Feb. Immune Netw. 2022. PMID: 35291650 Free PMC article. Review.
BRD2 compartmentalizes the accessible genome.
Xie L, Dong P, Qi Y, Hsieh TS, English BP, Jung S, Chen X, De Marzio M, Casellas R, Chang HY, Zhang B, Tjian R, Liu Z. Xie L, et al. Among authors: jung s. Nat Genet. 2022 Apr;54(4):481-491. doi: 10.1038/s41588-022-01044-9. Epub 2022 Apr 11. Nat Genet. 2022. PMID: 35410381 Free PMC article.
Prof. Michael Sela (1924-2022).
Arnon R, Mozes E, Jung S, Pecht I. Arnon R, et al. Among authors: jung s. Eur J Immunol. 2022 Sep 15. doi: 10.1002/eji.202250139. Online ahead of print. Eur J Immunol. 2022. PMID: 36108107 No abstract available.
Dietary Fructose and Fructose-Induced Pathologies.
Jung S, Bae H, Song WS, Jang C. Jung S, et al. Annu Rev Nutr. 2022 Aug 22;42:45-66. doi: 10.1146/annurev-nutr-062220-025831. Annu Rev Nutr. 2022. PMID: 35995049 Review.
Micrococcin P2 Targets Clostridioides difficile.
Son YJ, Kim YR, Oh SH, Jung S, Ciufolini MA, Hwang HJ, Kwak JH, Pai H. Son YJ, et al. Among authors: jung s. J Nat Prod. 2022 Aug 26;85(8):1928-1935. doi: 10.1021/acs.jnatprod.2c00120. Epub 2022 Jul 11. J Nat Prod. 2022. PMID: 35816693 Review.
Therapeutic Targeting of Macrophage Plasticity Remodels the Tumor-Immune Microenvironment.
Jang HJ, Lee HS, Yu W, Ramineni M, Truong CY, Ramos D, Splawn T, Choi JM, Jung SY, Lee JS, Wang DY, Sederstrom JM, Pietropaolo M, Kheradmand F, Amos CI, Wheeler TM, Ripley RT, Burt BM. Jang HJ, et al. Among authors: jung sy. Cancer Res. 2022 Jul 18;82(14):2593-2609. doi: 10.1158/0008-5472.CAN-21-3506. Cancer Res. 2022. PMID: 35709756
11,335 results
You have reached the last available page of results. Please see the User Guide for more information.